These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21623918)

  • 41. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
    Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
    Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
    [No Abstract]   [Full Text] [Related]  

  • 42. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
    Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
    Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
    [No Abstract]   [Full Text] [Related]  

  • 43. WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Falconi G; Fabiani E; Ottone T; Piciocchi A; Lavorgna S; Criscuolo M; Fianchi L; Gurnari C; Postorino M; Picardi A; Palmieri R; Lo-Coco F; Voso MT
    Leuk Lymphoma; 2020 Apr; 61(4):979-982. PubMed ID: 31797711
    [No Abstract]   [Full Text] [Related]  

  • 44. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Azacitidine in lower-risk myelodysplastic syndromes.
    Santini V
    Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
    Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
    Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829
    [No Abstract]   [Full Text] [Related]  

  • 47. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
    Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I
    Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231
    [No Abstract]   [Full Text] [Related]  

  • 48. Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agent.
    Orciuolo E; Cecconi N; Galimberti S; Papineschi F; Petrini M
    Leuk Res; 2007 Sep; 31(9):1321-3. PubMed ID: 17113639
    [No Abstract]   [Full Text] [Related]  

  • 49. New agents in the treatment of MDS.
    List AF
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623
    [No Abstract]   [Full Text] [Related]  

  • 50. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

  • 51. Azacitidine.
    Issa JP; Kantarjian H
    Nat Rev Drug Discov; 2005 May; Suppl():S6-7. PubMed ID: 15962522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 53. Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
    Becherer K; Golda N; Feldman M; Diaz-Arias A; Caldwell C
    J Cutan Pathol; 2009 Sep; 36(9):1024-6. PubMed ID: 19674208
    [No Abstract]   [Full Text] [Related]  

  • 54. Hematology: Azacitidine improves survival in myelodysplastic syndromes.
    Rose MG
    Nat Rev Clin Oncol; 2009 Sep; 6(9):502-3. PubMed ID: 19707240
    [No Abstract]   [Full Text] [Related]  

  • 55. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
    Turturro F; Leary C; Stephens J; Veillon D; Lowery-Nordberg M
    J Clin Oncol; 2010 Aug; 28(22):e380-1. PubMed ID: 20458054
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
    Ogata K; Sei K; Kawahara N; Yamamoto Y
    Br J Haematol; 2020 May; 189(4):e144-e147. PubMed ID: 32130725
    [No Abstract]   [Full Text] [Related]  

  • 57. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
    Voso MT; Fabiani E; Piciocchi A; Matteucci C; Brandimarte L; Finelli C; Pogliani E; Angelucci E; Fioritoni G; Musto P; Greco M; Criscuolo M; Fianchi L; Vignetti M; Santini V; Hohaus S; Mecucci C; Leone G
    Leukemia; 2011 Dec; 25(12):1910-3. PubMed ID: 21760590
    [No Abstract]   [Full Text] [Related]  

  • 58. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
    Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N
    Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576
    [No Abstract]   [Full Text] [Related]  

  • 59. Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
    Jennane S; El Haddad M; Mahtat EM; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2017 Dec; 75(6):713-714. PubMed ID: 29043987
    [No Abstract]   [Full Text] [Related]  

  • 60. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
    Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
    Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.